AIMS: This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR). METHODS:Adult renal transplant recipients (n = 361) oncyclosporine-based immunosuppression were followed for the first 6 months after transplantation. The incidence of DGF and AR were documented as well as the prevalence of SCR at 6 months in surveillance biopsies. Demographic, transplant-related factors, pharmacological and pharmacogenetic factors (ABCB1, CYP3A5, CYP3A4, CYP2C8, NR1I2, PPP3CA and PPP3CB) were analysed in a combined approach in relation to the occurrence of DGF, AR and prevalence of SCR at month 6 using a proportional odds model and time to event model. RESULTS: Fourteen per cent of the patients experienced at least one clinical rejection episode and only DGF showed a significant effect on the time to AR. The incidence of DGF correlated with a deceased donor kidney transplant (27% vs. 0.6% of living donors). Pharmacogenetic factors were not associated with risk for DGF, AR or SCR. A deceased donor kidney and acute rejection history were the most important determinants for SCR, resulting in a 52% risk of SCR at 6 months (vs. 11% average). In a sub-analysis of the patients with AR, those treated with rejection treatment including ATG, significantly less frequent SCR was found in the 6-month biopsy (13% vs. 50%). CONCLUSIONS: Transplant-related factors remain the most important determinants of DGF, AR and SCR. Furthermore, rejection treatment with depleting antibodies effectively prevented SCR in 6-month surveillance biopsies.
RCT Entities:
AIMS: This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR). METHODS: Adult renal transplant recipients (n = 361) on cyclosporine-based immunosuppression were followed for the first 6 months after transplantation. The incidence of DGF and AR were documented as well as the prevalence of SCR at 6 months in surveillance biopsies. Demographic, transplant-related factors, pharmacological and pharmacogenetic factors (ABCB1, CYP3A5, CYP3A4, CYP2C8, NR1I2, PPP3CA and PPP3CB) were analysed in a combined approach in relation to the occurrence of DGF, AR and prevalence of SCR at month 6 using a proportional odds model and time to event model. RESULTS: Fourteen per cent of the patients experienced at least one clinical rejection episode and only DGF showed a significant effect on the time to AR. The incidence of DGF correlated with a deceased donor kidney transplant (27% vs. 0.6% of living donors). Pharmacogenetic factors were not associated with risk for DGF, AR or SCR. A deceased donor kidney and acute rejection history were the most important determinants for SCR, resulting in a 52% risk of SCR at 6 months (vs. 11% average). In a sub-analysis of the patients with AR, those treated with rejection treatment including ATG, significantly less frequent SCR was found in the 6-month biopsy (13% vs. 50%). CONCLUSIONS: Transplant-related factors remain the most important determinants of DGF, AR and SCR. Furthermore, rejection treatment with depleting antibodies effectively prevented SCR in 6-month surveillance biopsies.
Authors: James M Gloor; Ari J Cohen; Donna J Lager; Joseph P Grande; Mary E Fidler; Jorge A Velosa; Timothy S Larson; Thomas R Schwab; Matthew D Griffin; Mikel Prieto; Scott L Nyberg; Sylvester Sterioff; Walter K Kremers; Mark D Stegall Journal: Transplantation Date: 2002-06-27 Impact factor: 4.939
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Ingeborg A Hauser; Elke Schaeffeler; Stefan Gauer; Ernst H Scheuermann; Binytha Wegner; Jan Gossmann; Hanns Ackermann; Christian Seidl; Berthold Hocher; Ulrich M Zanger; Helmut Geiger; Michel Eichelbaum; Matthias Schwab Journal: J Am Soc Nephrol Date: 2005-03-16 Impact factor: 10.121
Authors: E Thervet; M A Loriot; S Barbier; M Buchler; M Ficheux; G Choukroun; O Toupance; G Touchard; C Alberti; P Le Pogamp; B Moulin; Y Le Meur; A E Heng; J F Subra; P Beaune; C Legendre Journal: Clin Pharmacol Ther Date: 2010-04-14 Impact factor: 6.875
Authors: Bum Soon Choi; Mi Jung Shin; Suk Joon Shin; Young Soo Kim; Yeong Jin Choi; Yong-Soo Kim; In Sung Moon; Suk Young Kim; Yong Bok Koh; Byung Kee Bang; Chul Woo Yang Journal: Am J Transplant Date: 2005-06 Impact factor: 8.086
Authors: Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman Journal: Transplantation Date: 2004-07-27 Impact factor: 4.939
Authors: F Moreso; D Seron; F O'Valle; M Ibernon; M Gomà; M Hueso; J M Cruzado; O Bestard; V Duarte; R García del Moral; J M Grinyó Journal: Am J Transplant Date: 2007-10-19 Impact factor: 8.086
Authors: Dirk Jan A R Moes; Rogier R Press; Oliver Ackaert; Bart A Ploeger; Frederike J Bemelman; Cheikh Diack; Judith A M Wessels; Tahar van der Straaten; Meindert Danhof; Jan-Stephan F Sanders; Jaap J Homan van der Heide; Henk Jan Guchelaar; Johan W de Fijter Journal: Br J Clin Pharmacol Date: 2016-05-10 Impact factor: 4.335
Authors: Patricia C Salgado; Fabiana Dv Genvigir; Claudia R Felipe; Helio Tedesco-Silva; Jose O Medina-Pestana; Sonia Q Doi; Mario H Hirata; Rosario Dc Hirata Journal: Pharmgenomics Pers Med Date: 2017-03-31